Medication in temporomandibular disorders and bruxism
Abstract
The aim of this thesis was to explore aspects of pharmaceutical intervention in temporomandibular disorders (TMDs) and bruxism. Sleep bruxism is a movement disorder that signals disturbed sleep and constitutes a significant health problem due to TMDs, headache and tooth wear. In Study I, medication was reviewed in patients referred for specialist treatment for TMDs. Female patients with myofascial pain used significantly more psychoactive medication, including antidepressants, tranquilizers, sedatives and hypnotics, compared with matched controls. These findings support other research demonstrating an overrepresentation of the diagnoses depression, anxiety, stress and sleep problems among TMD patients. Study II compared the effect of oral glucosamine sulfate on osteoarthritis in the temporomandibular joints with that of placebo. Glucosamine sulfate appeared to improve signs and symptoms over time, but it was not significantly superior to placebo. In Study III, the dopamine agonist, pramipexole, was investigated in severe sleep bruxism confirmed by polysomnographic/electromyographic monitoring. The severity of sleep bruxism was not reduced compared with control conditions, indicating that the involvement of the dopamine system in bruxism is less likely. In Study IV, the effects of botulinum toxin injections in the masticatory muscles, compared with placebo injections, were evaluated in subjects with cerebral palsy and bruxism. No significant differences between active and control injections in terms of subjective or objective oral functions could be observed at group level. In conclusion, the results were negative with respect to the evaluated pharmacologic remedies for TMDs and bruxism. There is a relative lack of controlled studies in this area. Considering the pronounced negative impact on quality of life that has been reported for these conditions, it should be an important task continuously to evaluate putative pharmacologic therapies in TMDs and bruxism.
Parts of work
I. Johansson Cahlin B, Samuelsson N, Dahlström L. Utilization of pharmaceuticals among patients with temporomandibular disorders: a controlled study. Acta Odontol Scand. 2006;64(3):187-92. ::PMID:: 16809198 II. Cahlin BJ, Dahlström L. No effect of glucosamine sulfate on osteoarthritis in the temporomandibular joints – a randomized, controlled, short-term study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(6):760-6. ::doi::10.1016/j.tripleo.2011.06.012 III. Cahlin BJ, Hedner J, Dahlström L. A randomised, open-label, cross-over study of the dopamine agonist, pramipexole, in patients with sleep bruxism. IV. Cahlin BJ, Lindberg C, Dahlström L. Cerebral palsy and bruxism: effects of botulinum toxin injections – a randomized, controlled trial
Degree
Doctor of Philosophy (Odontology)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Odontology. Department of Behavioral and Community Dentistry
Disputation
Fredagen den 10 juni 2016, kl 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Date of defence
2016-06-10
birgitta.johansson-cahlin@vgregion.se
Date
2016-05-23Author
Cahlin, Birgitta Johansson
Keywords
temporomandibular disorders
sleep bruxism
glucosamine sulfate
pramipexole
dopamine agonist
botulinum toxin
cerebral palsy
Publication type
Doctoral thesis
ISBN
978-91-628-9782-6 (print)
978-91-628-9783-3 (PDF)
Language
eng